Drug Pipeline

Semaglutide Pen Injector Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
7
Active Studies
6
Recruiting
2
Phase 3
7
Top Sponsors
Active Studies by Phase
Phase 4
1
Phase 3
2
Phase 2
3
Phase 1/2
1
Active Trials
NCT IDTitleConditionStatus
Phase 4
NCT06852391 JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle… Obesity (Disorder) Recruiting
Phase 3
NCT05819138 Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes Diabetes Mellitus, Type 1 Recruiting
NCT05569772 Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational… Glucose Intolerance After a Recent History of Gestational Diabetes Recruiting
Phase 2
NCT05254314 Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related… Asthma Recruiting
NCT05424003 Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After… NAFLD Recruiting
NCT05067621 Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and… Type 2 Diabetes Mellitus Active, Not Recruiting
Phase 1/2
NCT05746039 Feasibility of Semaglutide in Advanced Lung Disease Obesity Recruiting
Sponsors Running Semaglutide Pen Injector Trials
Yale University (1) Vanderbilt University Medical Center (1) University of Virginia (1) Universitaire Ziekenhuizen KU Leuven (1) University of Pennsylvania (1) University of Colorado, Denver (1) McMaster University (1)
Disease Areas
Diabetes (3) Obesity (3) Type 2 Diabetes (1) Asthma (1) NASH / MASH (1) Hypertension (1) COPD (1)
Get alerts when Semaglutide Pen Injector trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free